secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001193125-26-187243
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics regains Nasdaq bid price compliance; still faces MVLS deficiency
--------------------------------------------------------------------------------

- Regained compliance with Nasdaq minimum bid price rule (closing bid >= $1.00 for 10 consecutive business days through April 24, 2026).
- Still not compliant with Nasdaq market value of listed securities (MVLS) requirement (must be at least $50M); compliance period ends September 14, 2026.
- No assurance given that company will meet MVLS requirement or maintain other listing standards.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526187243/0001193125-26-187243-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526187243/d623526d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-187243

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer